Industry

Rockwell Medical Reacquires Distribution Rights for its Hemodialysis Concentrates Business from Baxter

Expects to be Profitable in 2024 WIXOM, Mich.–(BUSINESS WIRE)–$RMTI #concentrates–Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company is reacquiring its distribution rights to its hemodialysis concentrates products from Baxter … [Read more…]

NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research

Inclusion of Abcam validated antibodies in CosMx curated protein panel provides the first high-plex spatial multiomic solution at single-cell and subcellular resolution Data from the CosMx human immuno-oncology 64-plex protein panel will be presented at the 37th Annual Meeting of the Society of Immunotherapy of Cancer Conference (SITC) SEATTLE & CAMBRIDGE, United Kingdom–(BUSINESS WIRE)–#spatialbiology–NanoString Technologies, … [Read more…]

KA Imaging’s Reveal 35C Receives CE Mark Certificate

With the certification, the company can commercialize the detector in more than 30 new countries WATERLOO, Ontario–(BUSINESS WIRE)–#ECR2020–KA Imaging’s innovative Reveal™ 35C flat panel detector has received EU MDR CE Mark Certificate from the EU Notified Body. The X-ray detector, powered by patented SpectralDR™ technology, is now qualified for sale in any of the 27 … [Read more…]

DNA Script Strengthens Its Management Team with the Appointment of Bruno Poddevin as Senior Vice President of Business and Corporate Development

Poddevin joins DNA Script in a year of immense growth in hiring, financing, commercialization and collaborations. PARIS–(BUSINESS WIRE)–#DNASynthesis–DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, further strengthened its leadership team with the addition of Bruno Poddevin, Ph.D., who brings 30 years of experience in the oligo manufacturing industry to … [Read more…]

TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities. The current US clinical trials are run in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA and the Merck-Pfizer-Alliance. … [Read more…]

Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros

LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today announces the success of its fundraise for approximatively € 9.7 millions, including, on the one hand, a reserved offer intended to a category of … [Read more…]

Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin

Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023. ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, under clinical development for depression. ELE-101 is the second clinical-stage psychedelic compound in Beckley Psytech’s portfolio alongside BPL-003, … [Read more…]

Sensorion Will Attend In-Person the Jefferies London Healthcare Conference

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce Sensorion’s management team participation, in-person, in Jefferies London Healthcare Conference, taking place in London, UK, on November … [Read more…]

Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Trial met its primary endpoint with Onivyde® (irinotecan liposome injection) in the NALIRIFOX treatment regimen showing statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine regimen Study met key secondary endpoint of progression-free survival with a safety profile consistent with the previous study Clinical trial results will be presented at an upcoming medical … [Read more…]

BiomeBank Announces World First Regulatory Approval for Donor Derived Microbiome Drug

Formal Therapeutic Goods Administration (“TGA”) approval of BiomeBank’s first-generation donor derived microbiome-based therapy. BiomeBank to scale up its Good Manufacturing Practice (GMP) manufacturing facility to meet increasing global demand for its donor derived microbiome drug product -positioned for the treatment of recurrent C. difficile infection with a path to approval in additional conditions. ADELAIDE, Australia–(BUSINESS … [Read more…]